DK1416956T3 - Autologe T-celle-vaccinematerialer samt fremgangsmåde til deres fremstilling - Google Patents

Autologe T-celle-vaccinematerialer samt fremgangsmåde til deres fremstilling

Info

Publication number
DK1416956T3
DK1416956T3 DK02778249T DK02778249T DK1416956T3 DK 1416956 T3 DK1416956 T3 DK 1416956T3 DK 02778249 T DK02778249 T DK 02778249T DK 02778249 T DK02778249 T DK 02778249T DK 1416956 T3 DK1416956 T3 DK 1416956T3
Authority
DK
Denmark
Prior art keywords
methods
autologous
preparation
cell vaccine
vaccine materials
Prior art date
Application number
DK02778249T
Other languages
English (en)
Inventor
Jingwu Zhang
Original Assignee
Opexa Pharmaceuticals Inc
Baylor College Medicine
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Opexa Pharmaceuticals Inc, Baylor College Medicine filed Critical Opexa Pharmaceuticals Inc
Application granted granted Critical
Publication of DK1416956T3 publication Critical patent/DK1416956T3/da

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/0005—Vertebrate antigens
    • A61K39/0008—Antigens related to auto-immune diseases; Preparations to induce self-tolerance
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K2239/00—Indexing codes associated with cellular immunotherapy of group A61K39/46
    • A61K2239/31—Indexing codes associated with cellular immunotherapy of group A61K39/46 characterized by the route of administration
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K2239/00—Indexing codes associated with cellular immunotherapy of group A61K39/46
    • A61K2239/38—Indexing codes associated with cellular immunotherapy of group A61K39/46 characterised by the dose, timing or administration schedule
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/46—Cellular immunotherapy
    • A61K39/461—Cellular immunotherapy characterised by the cell type used
    • A61K39/4611—T-cells, e.g. tumor infiltrating lymphocytes [TIL], lymphokine-activated killer cells [LAK] or regulatory T cells [Treg]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/46—Cellular immunotherapy
    • A61K39/462—Cellular immunotherapy characterized by the effect or the function of the cells
    • A61K39/4621—Cellular immunotherapy characterized by the effect or the function of the cells immunosuppressive or immunotolerising
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/46—Cellular immunotherapy
    • A61K39/464—Cellular immunotherapy characterised by the antigen targeted or presented
    • A61K39/4643—Vertebrate antigens
    • A61K39/46432—Nervous system antigens
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/46—Cellular immunotherapy
    • A61K39/464—Cellular immunotherapy characterised by the antigen targeted or presented
    • A61K39/4643—Vertebrate antigens
    • A61K39/46433—Antigens related to auto-immune diseases; Preparations to induce self-tolerance
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A61P37/04—Immunostimulants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N5/00—Undifferentiated human, animal or plant cells, e.g. cell lines; Tissues; Cultivation or maintenance thereof; Culture media therefor
    • C12N5/06—Animal cells or tissues; Human cells or tissues
    • C12N5/0602—Vertebrate cells
    • C12N5/0634—Cells from the blood or the immune system
    • C12N5/0636—T lymphocytes

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Immunology (AREA)
  • Chemical & Material Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Animal Behavior & Ethology (AREA)
  • Engineering & Computer Science (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Cell Biology (AREA)
  • Microbiology (AREA)
  • Epidemiology (AREA)
  • Biomedical Technology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Mycology (AREA)
  • Organic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Zoology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Biotechnology (AREA)
  • Genetics & Genomics (AREA)
  • Neurology (AREA)
  • Wood Science & Technology (AREA)
  • Neurosurgery (AREA)
  • Rheumatology (AREA)
  • General Engineering & Computer Science (AREA)
  • Biochemistry (AREA)
  • Hematology (AREA)
  • Pain & Pain Management (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Hospice & Palliative Care (AREA)
  • Psychiatry (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
DK02778249T 2001-09-14 2002-09-12 Autologe T-celle-vaccinematerialer samt fremgangsmåde til deres fremstilling DK1416956T3 (da)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US09/952,532 US7658926B2 (en) 2001-09-14 2001-09-14 Autologous T-cell vaccines materials and methods
PCT/US2002/028874 WO2003024393A2 (en) 2001-09-14 2002-09-12 Autologous t-cell vaccines materials and method

Publications (1)

Publication Number Publication Date
DK1416956T3 true DK1416956T3 (da) 2008-09-01

Family

ID=25492995

Family Applications (2)

Application Number Title Priority Date Filing Date
DK02778249T DK1416956T3 (da) 2001-09-14 2002-09-12 Autologe T-celle-vaccinematerialer samt fremgangsmåde til deres fremstilling
DK10178920.4T DK2335720T3 (da) 2001-09-14 2002-09-12 Autolog T-cellevacciner mod multiple sclerose

Family Applications After (1)

Application Number Title Priority Date Filing Date
DK10178920.4T DK2335720T3 (da) 2001-09-14 2002-09-12 Autolog T-cellevacciner mod multiple sclerose

Country Status (22)

Country Link
US (2) US7658926B2 (da)
EP (3) EP2335720B1 (da)
JP (5) JP2005502721A (da)
KR (1) KR20040066787A (da)
CN (2) CN100346824C (da)
AT (1) ATE395076T1 (da)
AU (1) AU2002339914B2 (da)
BR (1) BR0212504A (da)
CA (1) CA2459969C (da)
DE (1) DE60226612D1 (da)
DK (2) DK1416956T3 (da)
ES (2) ES2418529T3 (da)
HK (1) HK1071698A1 (da)
HU (1) HUP0401519A3 (da)
IL (2) IL159998A0 (da)
MX (1) MXPA04001862A (da)
NZ (1) NZ530762A (da)
PL (1) PL210442B1 (da)
PT (2) PT1416956E (da)
RU (1) RU2302257C2 (da)
WO (1) WO2003024393A2 (da)
ZA (1) ZA200401502B (da)

Families Citing this family (11)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20020009448A1 (en) * 1997-09-19 2002-01-24 Leslie P. Weiner T-cell vaccination for the treatment of multiple sclerosis
US7658926B2 (en) * 2001-09-14 2010-02-09 Opexa Pharmaceuticals, Inc. Autologous T-cell vaccines materials and methods
US7744893B2 (en) * 2002-06-05 2010-06-29 Baylor College Of Medicine T cell receptor CDR3 sequences associated with multiple sclerosis and compositions comprising same
ES2545736T3 (es) * 2002-08-08 2015-09-15 Baylor College Of Medicine Aislamiento e identificación de células T
EP1583823A4 (en) * 2002-12-31 2006-02-22 Baylor College Medicine ISOLATION AND IDENTIFICATION OF CROSS-REACTIVE T CELLS
NZ546552A (en) * 2003-10-17 2009-10-30 Baylor College Medicine A method for increasing CD8+ cytotoxic T cell reponses and for treating multiple sclerosis
DK2016414T3 (da) * 2006-05-05 2015-12-07 Opexa Therapeutics T-celle-vaccine
WO2010000730A1 (en) * 2008-06-30 2010-01-07 Universitätsklinikum Heidelberg Immunosuppressive blood cells and methods of producing same
US20170246272A1 (en) * 2014-09-05 2017-08-31 Opexa Therapeutics, Inc. Compositions and methods for treating b cell mediated autoimmune disorders
CN109125717B (zh) * 2017-09-08 2022-02-22 江苏苏博生物医学股份有限公司 一种治疗慢性病的自体全细胞疫苗配方及其制备方法
US20210061875A1 (en) 2017-12-29 2021-03-04 The Henry M. Jackson Foundation For The Advancement Of Military Medicine, Inc. Compositions and methods for treating autoimmune disease

Family Cites Families (65)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JPS5852225A (ja) 1981-09-22 1983-03-28 Mitsui Pharmaceut Inc 脱髄疾患治療剤
US5766920A (en) 1982-08-11 1998-06-16 Cellcor, Inc. Ex vivo activation of immune cells
US4550086A (en) 1983-02-16 1985-10-29 Dana-Farber Cancer Institute, Inc. Monoclonal antibodies that recognize human T cells
IL69686A (en) 1983-09-11 1988-03-31 Yeda Res & Dev Compositions containing cell membrane proteins and process for their preparation
US4608365A (en) 1984-03-30 1986-08-26 University Of Southern California Treatment of neurologic functions
US4677061A (en) 1984-10-19 1987-06-30 Genetic Systems Corporation T-cell lymphocyte subset monitoring of immunologic disease
US4897389A (en) 1984-10-29 1990-01-30 Chaovanee Aroonsakul Treating central nervous system diseases
US4898856A (en) 1984-10-29 1990-02-06 Chaovanee Aroonsakul Method for treating central nervous system diseases
US4898857A (en) 1984-10-29 1990-02-06 Chaovanee Aroonsakul Treating control nervous system diseases
US4902680A (en) 1984-10-29 1990-02-20 Chaovanee Aroonsakul Treating central nervous system diseases
CA1296622C (en) 1986-08-12 1992-03-03 Jeffrey E. Anderson Method and apparatus for automated assessment of the immunoregulatory status of the mononuclear leukocyte immune system
US5849298A (en) 1987-06-24 1998-12-15 Autoimmune Inc. Treatment of multiple sclerosis by oral administration of bovine myelin
US5039660A (en) 1988-03-02 1991-08-13 Endocon, Inc. Partially fused peptide pellet
US5242687A (en) 1989-03-15 1993-09-07 Tkb Associates Limited Partnership Method of reducing cellular immune response involving T-cells using CD8-bearing antigen presenting cells
US6221352B1 (en) 1989-03-21 2001-04-24 The Immune Response Corporation Method of preventing the proliferation of Vβ14 or Vβ17-Expressing T cells
US5861164A (en) 1989-03-21 1999-01-19 The Immune Response Corporation Vaccination against diseases resulting from pathogenic responses by specific T cell populations
US5837246A (en) 1989-03-21 1998-11-17 The Immune Response Corporation Vaccination and methods against diseases resulting from pathogenic responses by specific T cell populations
US6207645B1 (en) 1989-03-21 2001-03-27 The Immune Response Corporation Vaccination and methods against diseases resulting from pathogenic responses by specific T cell populations
US5612035A (en) * 1989-03-21 1997-03-18 The Immune Response Corporation Vaccination against diseases resulting from pathogenic responses by specific T cell populations
US6007815A (en) 1989-03-21 1999-12-28 The Immune Response Corporation Anti-idiotype vaccination against diseases resulting from pathogenic responses by specific T cell populations
US5614192A (en) 1989-07-19 1997-03-25 Connective Therapeutics, Inc. T cell receptor peptides as therapeutics for immune-related disease
US5776459A (en) 1989-07-19 1998-07-07 Connetics Corporation TCR V beta 5 peptides
US5298396A (en) 1989-11-15 1994-03-29 National Jewish Center For Immunology And Respiratory Medicine Method for identifying T cells disease involved in autoimmune disease
IL97709A (en) 1990-03-30 2005-05-17 Brigham & Womens Hospital Use of an mbp peptide for the preparation of a medicament for the treatment of multiple sclerosis
WO1992001044A1 (en) 1990-07-06 1992-01-23 Allergene, Inc. Mouse/human heterohybrid cell line el41 and methods for the production of human monoclonal antibodies
US5668117A (en) 1991-02-22 1997-09-16 Shapiro; Howard K. Methods of treating neurological diseases and etiologically related symptomology using carbonyl trapping agents in combination with previously known medicaments
US5211952A (en) 1991-04-12 1993-05-18 University Of Southern California Contraceptive methods and formulations for use therein
US6083503A (en) 1991-08-28 2000-07-04 The United States Of America As Represented By The Department Of Health And Human Services Interleukin-2 stimulated T lymphocyte cell death for the treatment of autoimmune diseases, allergic responses, and graft rejection
US5480895A (en) 1991-09-27 1996-01-02 New York Society For The Relief Of The Ruptured And Crippled, Maintaining The Hospital For Special Surgery Method of producing antibodies to a restricted population of T lymphocytes, antibodies produced therefrom and methods of use thereof
US5298386A (en) * 1992-06-09 1994-03-29 Eastman Kodak Company In-line solvent incorporation for amorphous particle dispersions
US5545716A (en) 1992-09-08 1996-08-13 University Of Florida Superantigen agonist and antagonist peptides
WO1994020120A1 (en) 1993-03-12 1994-09-15 Cellcor, Inc. In vitro assay measuring degree of activation of immune cells
WO1994022451A1 (en) 1993-04-07 1994-10-13 Oklahoma Medical Research Foundation Selective regulation of b lymphocyte precursors by hormones
AU6376194A (en) 1993-05-14 1994-12-12 Dr. L. Willems-Instituut Human t cell monoclone, process for its production and its use, diagnostic of infectious diseases, autoimmune diseases, t-cell mediated allergies and cancer
IL110787A0 (en) 1993-08-27 1994-11-11 Sandoz Ag Biodegradable polymer, its preparation and pharmaceutical composition containing it
US5552300A (en) 1994-01-13 1996-09-03 T Cell Sciences, Inc. T cell antigen receptor V region proteins and methods of preparation thereof
US6410518B1 (en) * 1994-05-31 2002-06-25 Isis Pharmaceuticals, Inc. Antisense oligonucleotide inhibition of raf gene expression
US5723503A (en) 1994-09-28 1998-03-03 Thomas Jefferson University Biological treatment for rheumatoid arthritis
US6033661A (en) 1995-06-07 2000-03-07 Thomas Jefferson University Composition and method for allogenetic mononuclear cell immunotherapy
US5674487A (en) 1994-09-28 1997-10-07 Univ Jefferson Method for treating autoimmune diseases
US6096314A (en) 1994-10-07 2000-08-01 Yeda Research And Development Co. Ltd. Peptides and pharmaceutical compositions comprising them
FR2727117A1 (fr) 1994-11-18 1996-05-24 Geffard Michel Utilisation de conjugues de la polylysine pour la preparation de medicaments utiles dans le traitement des maladies neurodegeneratives et des affections degeneratives a caractere autoimmun
AU721898B2 (en) 1994-11-18 2000-07-20 Board Of Trustees Of The Leland Stanford Junior University Methods for treatment of multiple sclerosis using peptide analogues at position 91 of human myelin basic protein
US6218166B1 (en) 1994-12-09 2001-04-17 John Wayne Cancer Institute Adjuvant incorporation into antigen carrying cells: compositions and methods
US5874531A (en) 1995-03-07 1999-02-23 President And Fellows Of Harvard College Identification of self and non-self antigens implicated autoimmune disease
US5869057A (en) 1995-06-07 1999-02-09 Rock; Edwin P. Recombinant vaccines to break self-tolerance
SE9502921D0 (sv) 1995-08-23 1995-08-23 Astra Ab New compounds
US5739307A (en) 1995-08-28 1998-04-14 Washington University Polynucleotide encoding neurturin neurotrophic factor
US5716946A (en) 1996-02-13 1998-02-10 Wisconsin Alumni Research Foundation Multiple sclerosis treatment
US5750356A (en) 1996-05-31 1998-05-12 Anergen, Inc. Method for monitoring T cell reactivity
US5849886A (en) 1996-07-10 1998-12-15 Oy Aboatech Ab Extraction of myelin basic protein
US20010031253A1 (en) 1996-07-24 2001-10-18 Gruenberg Micheal L. Autologous immune cell therapy: cell compositions, methods and applications to treatment of human disease
US6130087A (en) 1996-10-07 2000-10-10 Fordham University Methods for generating cytotoxic T cells in vitro
EP0930887B1 (en) 1996-10-11 2002-12-18 The Regents of the University of California Cancer immunotherapy using tumor cells combined with mixed lymphocytes
US6054292A (en) 1997-07-18 2000-04-25 Incyte Pharmaceuticals, Inc. T-cell receptor protein
US20020009448A1 (en) 1997-09-19 2002-01-24 Leslie P. Weiner T-cell vaccination for the treatment of multiple sclerosis
US20020072493A1 (en) 1998-05-19 2002-06-13 Yeda Research And Development Co. Ltd. Activated T cells, nervous system-specific antigens and their uses
WO2000014116A1 (en) 1998-09-04 2000-03-16 Baylor College Of Medicine T cell peptides as therapeutics for immune-related disease
JP2003504005A (ja) 1999-02-23 2003-02-04 ベイラー カレッジ オブ メディスィン Ｔ細胞レセプターＶβ−Ｄβ−Ｊβ配列およびその検出法
US6187750B1 (en) 1999-08-25 2001-02-13 Everyoung Technologies, Inc. Method of hormone treatment for patients with symptoms consistent with multiple sclerosis
US6746670B2 (en) 2000-08-15 2004-06-08 Schering Corporation Regulatory T cells; methods
MXPA03001569A (es) 2000-08-22 2004-12-13 Baylor College Medicine Secuencia de vbeta-dbeta-jbeta del receptor de celula y metodos para su deteccion.
US7658926B2 (en) 2001-09-14 2010-02-09 Opexa Pharmaceuticals, Inc. Autologous T-cell vaccines materials and methods
WO2003042377A1 (en) 2001-11-07 2003-05-22 Kirin Beer Kabushiki Kaisha Expansion of t cells in vitro and expanded t cell populations
DE10224223A1 (de) * 2002-05-31 2003-12-11 Mann & Hummel Filter Filterelement, insbesondere zur Flüssigkeitsfilterung aus einem Gasstrom

Also Published As

Publication number Publication date
US20050186192A1 (en) 2005-08-25
ES2418529T3 (es) 2013-08-14
AU2002339914B2 (en) 2005-03-24
EP1946767B1 (en) 2013-12-04
HUP0401519A3 (en) 2009-04-28
US20030091578A1 (en) 2003-05-15
PT2335720E (pt) 2013-07-08
EP1946767A3 (en) 2008-07-30
DE60226612D1 (de) 2008-06-26
MXPA04001862A (es) 2005-03-07
JP2011168618A (ja) 2011-09-01
EP1416956B1 (en) 2008-05-14
PT1416956E (pt) 2008-08-26
ATE395076T1 (de) 2008-05-15
CN100346824C (zh) 2007-11-07
WO2003024393A3 (en) 2003-11-06
IL159998A0 (en) 2004-06-20
DK2335720T3 (da) 2013-07-08
CN101229370B (zh) 2015-09-02
HUP0401519A2 (hu) 2004-11-29
BR0212504A (pt) 2004-08-24
EP1416956A2 (en) 2004-05-12
WO2003024393A2 (en) 2003-03-27
JP2015017129A (ja) 2015-01-29
US7658926B2 (en) 2010-02-09
JP4889581B2 (ja) 2012-03-07
ES2306792T3 (es) 2008-11-16
ZA200401502B (en) 2005-01-26
EP2335720B1 (en) 2013-04-03
IL196900A (en) 2015-03-31
CA2459969C (en) 2014-12-02
CN101229370A (zh) 2008-07-30
CN1553812A (zh) 2004-12-08
NZ530762A (en) 2005-10-28
JP2016188238A (ja) 2016-11-04
EP1946767A2 (en) 2008-07-23
CA2459969A1 (en) 2003-03-27
EP1416956A4 (en) 2004-10-13
HK1071698A1 (en) 2005-07-29
EP2335720A1 (en) 2011-06-22
KR20040066787A (ko) 2004-07-27
PL210442B1 (pl) 2012-01-31
PL367306A1 (en) 2005-02-21
RU2302257C2 (ru) 2007-07-10
RU2004103626A (ru) 2005-03-27
JP2005502721A (ja) 2005-01-27
IL196900A0 (en) 2011-07-31
JP2007254492A (ja) 2007-10-04

Similar Documents

Publication Publication Date Title
IL196900A (en) Autologous T cell vaccine compositions
CY1121353T1 (el) Anti-tnf αντισωματα, συνθεσεις, μεθοδοi και χρησεις
HUP0300369A2 (hu) Többértékű antitestek és alkalmazásuk
DE60142508D1 (de) Menschliche aminoacyl-trna synthetase polypeptide zur regulation der angiogenese
BR0113109A (pt) Anticorpos antil-il-12, composições, métodos e usos
NO20001768D0 (no) Viruskapsomervaksine, fremgangsmåte til fremstilling samt anvendelse derav
DK1487485T3 (da) Imidazoquinolinadjuvanser til DNA-vacciner
YU19903A (sh) Novi receptor nukleinskih kiselina i polipeptida
DE60238472D1 (de) Abschwächung der immunogenizität von fusionsproteinen
MX9203458A (es) Segmentos inmunogenicos que contienen glicoproteinas quimericas de las glicoproteinas de virus sincitial respiratorio humano.
DK0851927T3 (da) Forbindelser til immunterapi og diagnosticering af tuberkulose
AU2003244855A1 (en) Method to enhance an immune response of nucleic acid vaccination
DE69435038D1 (de) Aktivin rezeptor-ähnliche kinase (alk), gehörend zur tgf rezeptorfamilie und/oder zur bmp rezeptorfamilie
WO2004015070A3 (en) Isolation and identification of t cells
WO2002072036A3 (en) Compositions and methods comprising west nile virus polypeptides
FR21C1005I2 (fr) Antigenes de streptococcus pyogenes et fragments d'adn correspondants
EE200500012A (et) Peptiid-pähine passiivne immunoteraapia ateroskleroosi raviks
TW200508246A (en) Anti-dengue virus antibodies, compositions, methods and uses
ATE401344T1 (de) T-zellen-epitope in erythropoietin
DK1423525T3 (da) Rekombinant MVA, der kan eksprimere HCV-strukturantigener
HUP0003511A2 (hu) Hepatitisz-B-vírus polipeptidek
DE60034460D1 (de) Verwendung von trehalose produzierenden prokaryotischen zellen als impfstoffe
GB0409559D0 (en) Polypeptide
EA200400534A1 (ru) Стимуляция тимозином генетической иммунизации
CY1108543T1 (el) Εμβολια dna που κωδικοποιουν βοηθητικες πρωτεϊνες του hiv